Dr. Adhikari is a boarded cytopathologist with subspecialty expertise in gynecologic and genitourinary pathology and is the gynecologic pathology team leader at OU. She actively collaborates with faculty on biomarker classification for platinum resistant ovarian tumors, is an invited advisory board member for Roche and Mersana Therapeutics, and an invited speaker at the CAP 2021 National Annual Meeting. She is also a collaborator for the Open Pathology Education Network, an initiative to enrich pathology educational resources worldwide.
Academic Section(s):
Pathology
Education:
- BS - Texas Lutheran University, Summa cum laude, Biology and Chemistry, Art (2000-2004)
- MD - University of Texas Medical Branch (2004-2008)
Board Certification(s):
- Diplomate in Cytopathology, American Board of Pathology
- Diplomate in Anatomic & Clinical Pathology, American Board of Pathology
Residency:
- Anatomic and Clinical Pathology, Mayo Clinic, Rochester, MN (2008-2012)
Fellowship:
- Cytopathology - Ohio State University College of Medicine, Columbus, OH (2012-2013)
Clinical/Research Interests:
- Cytopathology
- Gynecologic Pathology
- Genitourinary Pathology
- Endocrine Pathology
Funding:
Benbrook, D. M., Hagemann, I., Mutch, M. (MPIs); Role Adhikari, L. J.,Co-I
"Route 66 Endometrial Cancer SPORE," Sponsored by NIH/NCI
Grant/Contract Number: FOA # PAR-20-305
Current Funding (Total Cost per Year): $241,700.00
Total Direct Costs: $816,420.00
July 1, 2023 - June 30, 2028
Dwivedi, S. K., (PI); Role Adhikari, L. J., Co-I
"miR-195 Re-Expression: A therapeutic strategy for chemo-resistant ovarian cancer," Ovarian Cancer Research, Sponsored by DoD
Current Funding (Total Cost per Year): $175,000
August 2023 - August 2027
Select Honors and Accomplishments:
- Fred G. Silva Research Award - Department of Pathology, University of Oklahoma College of Medicine (2023)
- Faculty Leadership Program - University of Oklahoma College of Medicine (2018-2019)
Select Publications:
- Gilley P, Zhang, K. Abdoli N, Sadri Y, Adhikari LJ, Fung K-M, Qui Y. Utilizing a Pathomics Biomarker to Predict the Effectiveness of Bevacizumab in Ovarian Cancer Treatment. Bioengineering 2024 Jul 3;11(7):678. DOI: 10.3390/bioengineering11070678
- Williams EA, Montesion M, Lincoln V, Tse JY, Hiemenz MC, Mata DA, Shah BB, Shoroye A, Alexander BM, Werth AJ, Foley-Peres K, Milante RR, Ross JS, Ramkissoon SH, Williams KJ, Adhikari LJ, Zuna RE, LeBoit PE, Lin DI, Elvin JA. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract. Am J Surg Pathol. 2022 Jun 1;46(6):729-741. DOI: 10.1097/PAS.0000000000001862. PMID: 35034043; PMCID: PMC9093731.
- Han M, Bernadt CT, Murray B, Johnson SM, Jalaly JB, Garcia T, Adhikari LJ. Aptima HR-HPV testing from Diff-Quick-stained fine-needle aspiration smears of oropharyngeal squamous cell carcinoma. J Am Soc Cytopathol. 2016 Jul-Aug;5(4):221-226. doi: 10.1016/j.jasc.2016.05.001. Epub 2016 May 26. PMID: 31042512.
- Adhikari, L. J., Reynolds JP, Wakely PE Jr. Multi-institutional study of fine-needle aspiration for thyroid lymphoma. J Am Soc Cytopathol. 2016 May-Jun;5(3):170-176. doi: 10.1016/j.jasc.2015.11.002. Epub 2015 Nov 11. PMID: 31042520.
- Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer. 2010 Jun 25;17(3):623-36. doi: 10.1677/ERC-09-0318. PMID: 20385747.